<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a patient with longstanding <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD) developing recurrent <z:hpo ids='HP_0100806'>sepsis</z:hpo> and impaired neutrophil function tests </plain></SENT>
<SENT sid="1" pm="."><plain>His <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> was controlled with local steroids and <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> with only short exposure to <z:chebi fb="2" ids="2948">azathioprine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>His blood counts remained within <z:mpath ids='MPATH_458'>normal</z:mpath> range, but the marrow showed mild <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Repeated cytogenetic examinations revealed <z:mp ids='MP_0004027'>trisomies</z:mp> 8 and 9, which are typical for therapy related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Fluorescent in situ hybridization (FISH) study showed stable persistent <z:mp ids='MP_0004027'>trisomies</z:mp>, confined to the myeloid lineage, one year after discontinuation of <z:chebi fb="3" ids="9334">sulfasalazine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The long-term use of immunodulating agents in patients with CD is not without risks, and early therapy related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> might not be easily detected by blood count and <z:mp ids='MP_0000002'>morphology</z:mp> assessment alone </plain></SENT>
</text></document>